What the research found

The argument presented rests on a conceptual framework: chronic disease emerges not from random tissue degradation, but from persistent activation of the body's wound-repair and growth programs in the absence of actual injury. Visceral adiposity and smoking are proposed as the primary triggers—these send continuous inflammatory signals that the body interprets as systemic damage requiring repair, prompting fibrosis and pathological remodeling across multiple organs.

The empirical anchor cited is a 2010 Kaiser Permanente Colorado study in post-MI patients. Pharmacist-led, protocol-driven delivery of foundational medications (not specified here) achieved an 8-fold reduction in cardiovascular mortality but a 12-fold reduction in all-cause mortality. The interpretation: if drugs were merely opening blocked arteries, cardiovascular deaths should fall more steeply than total deaths. Instead, the larger total-mortality benefit suggests treatment addressed a root driver affecting cancer, dementia, and kidney disease simultaneously—consistent with suppression of a body-wide maladaptive repair state.

Why it matters for you

If this model holds, your body composition and smoking status function as master switches that either activate or silence a cascade affecting arterial stiffness, kidney fibrosis, retinal capillary fragility, and even cancer progression. This reframes visceral fat not as cosmetic or merely metabolic, but as an active inflammatory organ continuously broadcasting false alarm signals. For MyKine users, this justifies why fat loss and smoking cessation aren't incremental—they're foundational interventions that theoretically suppress pathology across multiple organ systems simultaneously.

The practical implication: biomarkers of systemic inflammation (hsCRP, IL-6, fibrinogen) and fibrosis may be more predictive of your long-term disease risk than LDL cholesterol alone. Your training and sleep protocols matter not just for performance, but because they suppress visceral fat and inflammatory tone. Similarly, supplements or peptides targeting inflammation or metabolic health might amplify benefit if combined with aggressive fat loss, rather than offsetting poor body composition.

Caveats

• Single study citation, mechanism inferred: The Kaiser study is real but the causal interpretation—that a unified "repair crew" malfunction explains the mortality benefit—is deductive reasoning, not directly proven by the data presented
• Medications not specified: The study doesn't detail which drugs were used, so the active mechanism remains unknown
• Observational framing: Post-MI populations are highly selected; applicability to primary prevention unclear
• No mechanistic proof in humans: The visceral fat → inflammatory signal → organ fibrosis chain is plausible but supported here mainly by conceptual analogy, not molecular evidence in the text